LUNG CANCER

During a virtual Targeted Oncology Case-Based Roundtable event, Rodolfo Bordoni, MD, discussed recent clinical trials in the extensive-stage small cell lung cancer space.

Jessica Bauman, MD, reviewed data from the LIBRETTO-001 and ARROW trials which show the efficacy and safety of selpercatinib and pralsetinib for the treatment of patients with RET fusion-positive lung cancer.

The FDA has granted a priority review to mobocertinib as a treatment for adult patients with EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer, as detected by an FDA-approved test, and who have received prior platinum-based chemotherapy.

In an interview with Targeted Oncology following the FDA approval announcement for trilaciclib, Jared Weiss, MD, an assistant professor of medicine at the University of North Carolina Chapel Hill, discusses the use of trilaciclib in clinical practice and how it can improve patient quality-of-life by reducing the rate of neutropenia.

An expert in the treatment of lung cancer gives insight for the sequencing of ALK inhibitors following disease progression, highlighting the instances of the development of brain involvement and rebiopsy.

An expert in the treatment of lung cancer gives insight for the sequencing of ALK inhibitors following disease progression, highlighting the instances of the development of brain involvement and rebiopsy.

Karen Reckamp, MD, discusses the design, practical implications, and important findings from the ALTA-1L clinical trial.

An expert in the treatment of lung cancer discusses the use of brigatinib in this patient case and in general use for ALK+ metastatic NSCLC.

Karen Reckamp, MD, reviews recent therapeutic findings and the treatment spectrum for ALK+ NSCLC, as well as her clinical experience in using some of these treatments.

Karen Reckamp, MD, provides an overview of the case of a 68-year-old woman with ALK+ NSCLC, including the initial presentation, clinical work-up, treatment, and the importance of molecular testing.

Karen Reckamp, MD, comments on the management and treatment of a 68-year-old woman with ALK+ NSCLC, as well as data demonstrated in the ALTA-1L trial, use of brigatinib, and her own clinical experiences.

For patients non–small cell lung cancer who previously progressed on chemotherapy and immune checkpoint inhibitors, ceralasertib plus durvalumab proved effective compared with patients with the same profile who received durvalumab alone, according to findings from the ongoing HUDSON study.

During a virtual Targeted Oncology Case-Based Roundtable event, Alexander Spira, MD, PhD, discusses when the use of durvalumab followed by chemoradiotherapy is appropriate for patients with unresectable stage III non–small cell lung cancer.

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer, according to findings from a phase 2 trial presented in a poster at the American Association for Cancer Research Annual Meeting 2021.

During a virtual Targeted Oncology Case-Based Roundtable event, Kartik Konduri, MD, discussed the case of a 58-year-old patients with small cell lung cancer.

After treatment with savolitinib, undetectability of MET Exon 14 in the circulating tumor DNA of patients with non‒small cell lung cancer was found to be associated with prolonged progression-free survival, and overall survival.

Neoadjuvant nivolumab added to chemotherapy lead to an improvement in pathological complete responses, compared with chemotherapy alone, as treatment of patients with resectable non-small cell lung cancer.

Schlafen-11 expression may serve as a predictive biomarker for response to select treatments in patients with small cell lung cancer.

TPX-0046, a next-generation RET inhibitor demonstrated preliminary clinical activity in patients with RET-driven cancers who were treated in the phase 1/2 SWORD-1 clinical trial.

Perliminary analyses of 2 cohorts from the phase 2 multicohort ZENITH20 trial evaluating poziotinib show clinical activity and tolerability for the tyrosine kinase inhibitor in patients with non–small cell lung cancer harboring EGFR and HER2 exon 20 insertions.

During a virtually held Targeted Oncology Case-Based Roundable event, Meghan Mooradian, MD, discussed the case of a 63-year-old patient diagnosed with non–small cell lung cancer.

An update from the phase 3 IMpower010 study shows that the study has met its primary end point of improvement in disease-free survival with atezolizumab versus use of best supportive care as treatment of patients with non–small cell lung cancer.

Sotorasib demonstrated significant benefit in patients with KRAS G12C–mutated advanced non–small cell lung cancer who progressed after standard treatment, according to results from the phase 2 portion of the CodeBreaK 100 trial .

Jessica Donnington, MD, led a discussion with a group of peers regarding treatment of non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

The FDA has granted a fast-track designation to the tyrosine kinase inhibitor, poziotinib for the treatment of previously treated patients with non-small cell lung cancer whose tumors harbor a HER2 exon 20 mutation.